Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2090314 in Acute Leukemia
NCT01214603Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2010
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of LY2090314 in acute myeloid leukemia (AML) (3 cohorts), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With 1 or More Study Drug-Related Adverse Events (AEs) or Any Serious AEs (SAEs). Started Nov 2010; status: completed.
02
Drugs
LY2090314
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01214603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01214603.